A Multicenter Phenotype-Genotype Analysis of LGMD Patients in China

Sponsor
Huashan Hospital (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT04989751
Collaborator
(none)
350
1
40.8
8.6

Study Details

Study Description

Brief Summary

Limb-girdle muscular dystrophies (LGMD) are a series of rare progressive genetic disorders that are characterized by wasting and weakness of the voluntary proximal muscles. The onset of the disease is usually at young age, and most patients will be wheelchair-bound due to the progressive deterioration. Since currently genetic therapies for this disease are still immature, better natural history and genotype-phenotype studies are needed for preparing future therapies.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Electromyography
  • Diagnostic Test: IDEAL MRI

Detailed Description

This is multicentered-based, prospective, and observational study, which mainly focuses on the diagnosis and progression of limb-girdle muscular dystrophies (LGMD) in China. We collect patient data including basic information, strength evaluations, genetic data, electromyography results, pathology imaging from muscle biopsies, and MRIs. Previously collected patient data may also be enrolled in this study.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
350 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Multicenter Phenotype-Genotype Analysis of Limb Girdle Muscular Dystrophy Patients in China
Actual Study Start Date :
Jul 7, 2021
Anticipated Primary Completion Date :
Jul 1, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
LGMD patients

Diagnostic Test: Electromyography
Electromyography (EMG) would be used at the baseline for dignoisis and furtue analysis.

Diagnostic Test: IDEAL MRI
Muscle-speciifc sequences (e.g. IDEAL) would be used to scan patients at baseline and follow-up stages to characterize the fat fraction and atrophy in different muscles.

Outcome Measures

Primary Outcome Measures

  1. Change in mobility [Baseline, Year 1, Year 3]

    The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.

Secondary Outcome Measures

  1. Change in muscle fat infiltration [Baseline, Year 1, Year 3]

    The muscle-specific fat fraction can be calculated with special MRI sequences such as IDEAL or Dixon in the region of interest. Our previous study found that the fat fraction of semitendinosus positively correlated with the length LGMD R1/R2 duration.

  2. Change in motor performance [Baseline, Year 1, Year 3]

    The North Star Ambulatory Assessment (NSAA) is a 17-item rating scale that is used to measure functional motor abilities in ambulant patients with Duchenne Muscular Dystrophy

Eligibility Criteria

Criteria

Ages Eligible for Study:
10 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Identified with variants regarding LGMD related genes revealed by genetic sequencing

  • Progressive weakness involving shoulder girdle and/or pelvic girdle

  • Myopathic changes in electromyography or in pathological studies

Exclusion Criteria:
  • Identified with variants in other genes (non-LGMD related) that may cause muscular dystrophies

Contacts and Locations

Locations

Site City State Country Postal Code
1 Huashan Hospital Shanghai China 200040

Sponsors and Collaborators

  • Huashan Hospital

Investigators

  • Study Director: Chongbo Zhao, PhD, Huashan Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Chongbo Zhao, Professor, Huashan Hospital
ClinicalTrials.gov Identifier:
NCT04989751
Other Study ID Numbers:
  • KY2019-409
First Posted:
Aug 4, 2021
Last Update Posted:
Aug 4, 2021
Last Verified:
Aug 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Chongbo Zhao, Professor, Huashan Hospital

Study Results

No Results Posted as of Aug 4, 2021